| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 99 |
| 1 | VEDOLIZUMAB | 67 |
| 2 | INFLIXIMAB | 57 |
| 3 | METHOTREXATE SODIUM | 41 |
| 4 | METHOTREXATE | 35 |
| 5 | PREDNISONE | 35 |
| 6 | AZATHIOPRINE | 33 |
| 7 | PANTOPRAZOLE | 29 |
| 8 | USTEKINUMAB | 29 |
| 9 | ADALIMUMAB-ADAZ | 28 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | INFLIXIMAB-DYYB | 20 | 0.0058 |
| 1 | ADALIMUMAB-RYVK | 2 | 0.0018 |
| 2 | ADALIMUMAB-AFZB | 4 | 0.0015 |
| 3 | CLEMASTINE FUMARATE | 2 | 0.0014 |
| 4 | CHOLESTYRAMINE | 11 | 0.0009 |
| 5 | VEDOLIZUMAB | 67 | 0.0008 |
| 6 | SKIN PROTECTANT | 2 | 0.0007 |
| 7 | MESALAMINE | 21 | 0.0007 |
| 8 | TEDUGLUTIDE | 10 | 0.0007 |
| 9 | CALCIUM POLYCARBOPHIL | 2 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 78 |
| 1 | Corticosteroid [EPC] | 73 |
| 2 | Integrin Receptor Antagonist [EPC] | 67 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 65 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 35 |
| 5 | Purine Antimetabolite [EPC] | 33 |
| 6 | Vitamin C [EPC] | 31 |
| 7 | Interleukin-12 Antagonist [EPC] | 29 |
| 8 | Interleukin-23 Antagonist [EPC] | 29 |
| 9 | Janus Kinase Inhibitor [EPC] | 27 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bile Acid Sequestrant [EPC] | 11 | 0.0009 |
| 1 | Integrin Receptor Antagonist [EPC] | 67 | 0.0008 |
| 2 | GLP-2 Analog [EPC] | 10 | 0.0007 |
| 3 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 4 | 0.0006 |
| 4 | Semifluorinated Alkane [EPC] | 1 | 0.0004 |
| 5 | mu-Opioid Receptor Agonist [EPC] | 1 | 0.0003 |
| 6 | Purine Antimetabolite [EPC] | 33 | 0.0003 |
| 7 | Phosphodiesterase 3 Inhibitor [EPC] | 2 | 0.0003 |
| 8 | Calcitonin [EPC] | 1 | 0.0003 |
| 9 | Aluminum Complex [EPC] | 7 | 0.0003 |